COMBI-i: A phase 3 study of the anti-PD1 antibody PDR001 in combination with dabrafenib (D) and trametinib (T) in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma

Home / Abstract / COMBI-i: A phase 3 study of the anti-PD1 antibody PDR001 in combination with dabrafenib (D) and trametinib (T) in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma